ArticleCureus2025
The Effectiveness of Hypomethylating Agents in Elderly Patients With Acute Myeloid Leukemia: Insights From a Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute myeloid leukemia (AML) is an aggressive hematologic malignancy mainly affecting older adults. It presents significant challenges due to unfavorable cytogenetic characteristics and associated comorbidities, which restrict treatment options. Addressing these complexities is essential for improving patient outcomes. Hypomethylating agents (HMAs) such as azacitidine (AZA) and decitabine (DAC) are standard treatments for elderly patients unfit for intensive chemotherapy. The introduction of Venetoclax (Ven), a selective BCL-2 inhibitor, has shown promise in improving treatment outcomes.
methodsA retrospective analysis was conducted on 82 elderly AML patients treated at the Coltea Clinical Hospital, Bucharest, Romania, between January 2017 and December 2023. Patients received non-intensive chemotherapy with either AZA, DAC, LDAC, or their combination with Venetoclax. Clinical, cytogenetic, and molecular parameters were documented, and survival outcomes were analyzed using the Kaplan-Meier method. Statistical significance was assessed using the log-rank test and Cox proportional hazard regression. Results: The median overall survival (OS) was seven months among the patients receiving a single line of therapy. By contrast, in those treated with a second-line regimen that included Venetoclax, OS increased to 11 months. Although the sample size was small, this difference reached statistical significance (p = 0.038). Transfusion independence was significantly higher in Venetoclax-treated patients. Conclusion: Hypomethylating agents, in combination with Venetoclax, have emerged as the standard of care for elderly patients with AML, offering superior survival and response rates. Nevertheless, further therapeutic advancements are crucial to enhance treatment outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.